MissionIR would like to highlight
Advaxis (
OTCBB:ADXS), a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In the company’s news,
Advaxis has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for ADXS-HPV, the company’s lead drug candidate for the treatment of human papillomavirus (HPV)-associated anal cancer.
ADXS reports that from 1973-2000 the incidence of anal cancer in the United States increased by 160 percent among men and by 78 percent among women, 84 percent of which are caused by HPV. Individuals suffering from anal cancer face limited treatment options, and ADXS’ goal is to elongate survival. ADXS-HPV is currently beings studied for this indication in a phase1/2 clinical trial.
“We are very pleased to have been granted an orphan drug designation for ADXS-HPV in this unmet medical need,” Dr. Robert Petit, chief scientific officer of ADXS, stated in the press release. “Patients with anal cancer have limited treatment options and we hope to improve their survival by developing ADXS-HPV for this indication. We will continue the ongoing phase 1/2 study being coordinated by Brown University Oncology Group that is evaluating the safety and efficacy of ADXS-HPV when combined with standard chemotherapy and radiation treatment in patients with anal cancer.”
Orphan Drug Designation is awarded to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the United States. The designation entitles the sponsor to clinical protocol assistance with the FDA, as well as federal grants, tax credits, and the possibility for a seven-year market exclusivity period.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
